Tested Applications
| Positive WB detected in | HT-29 cells, COLO 320 cells, HeLa cells, HepG2 cells, MDA-MB-453s cells, PC-3 cells, U-937 cells |
| Positive IP detected in | HepG2 cells |
| Positive IHC detected in | human ovary tumor tissue, human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | Hela cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
11921-1-AP targets RASSF6 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag2565 Product name: Recombinant human RASSF6 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-300 aa of BC058835 Sequence: MAHQYPSWIFINEKTFITREQLNSLLKTYNIFYENQKNLHILYGETEDGKLIVEGMLDIFWGVKRPIQLKIQDEKPFSSFTSMKSSDVFSSKGMTRWGEFDDLYRISELDRTQIPMSEKRNSQEDYLPYHSNTLKPHAKDEPDSPVLYRTMSEAALVRKRMKPLMMDRKERQKNRASINGHFYNHEIENSPQDFALHIIFATGEQRRLKKTDIPLLQRLLQGPSEKNARIFLMDKDAEEISSDVAQYINFHFSLLESILQRLNEEEKREIQRIVTKFNKEKAIILKCLQNKLVIKTETTV Predict reactive species |
| Full Name | Ras association (RalGDS/AF-6) domain family member 6 |
| Calculated Molecular Weight | 369 aa, 43 kDa |
| Observed Molecular Weight | 43 kDa |
| GenBank Accession Number | BC058835 |
| Gene Symbol | RASSF6 |
| Gene ID (NCBI) | 166824 |
| RRID | AB_874225 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q6ZTQ3 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for RASSF6 antibody 11921-1-AP | Download protocol |
| IHC protocol for RASSF6 antibody 11921-1-AP | Download protocol |
| IP protocol for RASSF6 antibody 11921-1-AP | Download protocol |
| WB protocol for RASSF6 antibody 11921-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The RASSF6 antibody (Cat# 11921-1-AP) has 14 citations published in journals including Molecular Cancer, Oncotarget, Journal of Genetics and Genomics, World Journal of Gastroenterology, Journal of Cellular Physiology, Annals of Surgical Oncology, Epigenetics, Molecular and Cellular Biology, Biochemical and Biophysical Research Communications, Onco Targets and Therapy, and Genes Cells. Research fields span tumor suppression, epigenetic inactivation, epithelial-mesenchymal transition, apoptosis, cell cycle regulation, Hippo signaling, p53 pathway, and NF-κB signaling across leukemia, colorectal, gastric, pancreatic, breast, melanoma, esophageal, and bladder cancers.
| Species | Application | Title |
|---|---|---|
Mol Cancer The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. | ||
J Genet Genomics RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.
| ||
World J Gastroenterol Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. | ||
Oncotarget RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer. | ||
J Cell Physiol MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer. | ||
Ann Surg Oncol Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery. |























